Founded in 1996, Kelun Group has developed into a modern pharmaceutical group, with more than 90 subsidiaries (branches) both at home and abroad, all this rapid development took place within just 20 years. On June 3, 2010, the bell at Shenzhen Stock Exchange rang to declare the listing of Kelun Pharmaceutical (SZ002422), the industrial segment of the Kelun Group. That memorable day marked the entrance of the biggest manufacturer and distributor of IV Solutions into the capital market.
Kelun Group´s sales revenues in 2015 exceeded RMB 39 billion, and profit tax was over RMB 2 billion. According to the 2012 Sales Ranking of Chinese Drug Circulation Industry released by the Ministry of Commerce and the Pharmaceutical Statistic Annals of the Ministry of Industry and Information Technology (MIIT), the business and industrial segments of the Kelun Group ranked within the Top 10.
As the industrial segment of the Kelun Group, Kelun Pharmaceutical is specialized in manufacture and sale of 578 different products in 959 specifications, including LVP (IV Solutions), SVP (small volume parenterals), sterile powders for injections(including dispensed & lyophilized), tablets, capsules, granules, oral solutions, dialysis solutions, APIs, pharmaceutical packaging materials, medical devices, and antibiotic intermediates, among which 267 specifications in 110 varieties belong to IV solutions; 596 specifications in 378 varieties belong to pharmaceutical products in other dosage forms; 47 specifications in 45 varieties belong to APIs; 9 varieties belong to antibiotic intermediates; 32 varieties belong to pharmaceutical packaging materials; 8 specifications in 4 varieties belong to medical devices. Kelun is the pharmaceutical manufacturing enterprise with the largest number of different products and packaging forms in the IV solution industry of China. In terms of specific products, 117 varieties of Kelun products have been included in the National Essential Drugs List. At present, the company is the largest pharmaceutical group with the most complete industrial chain in China.
Kelun Pharmaceutical was honored with the “Corporate Social Responsibility Contribution Award” of the Chinese Pharmaceutical Enterprises Association and Network Center of People’s Daily jointly in September 2008. In the same year, Kelun Pharmaceutical was honored as “Exemplary Enterprise of Hi-Tech Industries (Pillar and New Material Sectors) in Sichuan Province” by Sichuan Provincial People’s Government. On December 30, 2008, the company was awarded as “Hi-Tech Enterprise” by the Science & Technology Department of Sichuan Province, Sichuan Provincial Department of Finance, Sichuan Provincial Office, SAT and Sichuan Local Taxation Bureau jointly.
In August 2009, Kelun Pharmaceutical was granted the “Outstanding Contribution Award of China Pharmaceutical Packaging Business” by the China Pharmaceutical Packaging Association. On October 30, 2009, Kelun Pharmaceutical was approved by the Ministry of Science and Technology to set up the “National Engineering Research Center of Large Volume Parenteral Preparations” and listed for the first group of building programs for the National Engineering Technology Research Center in 2009. On November 6, 2009, Kelun Pharmaceutical was honored to be the “National Recognized Enterprise Technology Center” by National Development and Reform Commission (NDRC), Ministry of Science and Technology (MOST), Ministry of Finance, National General Customs Administration and State Administration of Taxation jointly.
In April 2011, Kelun Pharmaceutical was approved to be “The Third Batch of State Innovative Enterprise” by Ministry of Science and Technology, State-Owned Assets Supervision and Administration Commission of the State Council, and All-China Federation of Labor jointly. In June 2011, Kelun Pharmaceutical was regarded as the first group of “State Exemplary Enterprise of Technology Innovation” by the Ministry of Industry and Information Technology, Ministry of Finance jointly, being the only pharmaceutical enterprise in Sichuan Province to be awarded; in November 2011, the company was classified as “National and Local Joint Engineering Laboratory” by the National Development and Reform Commission (NDRC).
In 2013, Kelun Pharmaceutical was awarded as the first “Model Enterprises of Industrial Brand Cultivation” and “National Model Enterprises of Good Combination of Informatization and Industrialization” by the MIIT, as well as “Contract-Honoring and Credit-Valuing Enterprise” by the State Administration for Industry and Commerce (SAIC). In May 2014, the company was regarded as "Pilot Enterprise of Implementing Informatization and Industrialization Combined Management System" by the MIIT, being the only pharmaceutical enterprise in Sichuan Province to be awarded.In Sept. 2015, the company was identified as “Quality Benchmark for National Industrial Enterprises of the Year 2015”by the MIIT.In addition, "Kelun" and "KL KELUN" trademarks are both rated as a "well-known trademark in China" by the SAIC. The company has also been identified as Sichuan Academician (Expert) Workstation jointly by Sichuan Party Committee Organization Department of CPC, Sichuan Provincial Economic and Information Commission, State-owned Assets Supervision and Administration Commission of Sichuan Province, Education Department of Sichuan Province, Science & Technology Department of Sichuan Province, Human Resources and Social Security Department of Sichuan Province and Sichuan Association for Science and Technology.
Since its foundation, Kelun Pharmaceutical has invested hundreds of millions of RMB in independent R & D and has fully mastered the core production technology of IV solutions. In 2005, the Collapsible PP Bottle (Uniflex®), an exclusive patented product of Kelun Pharmaceutical with several patented technologies entered the market successfully. The invention of Uniflex® embodies the latest research results of China’s contemporary manufacturing technology of IV solutions, also representing the trend of development of China’s IV solution packaging in the future. The product is an original invention both at home and abroad, and is now changing profoundly the current situation of the IV solution industry. In November 2008, the Uniflex® was recognized as “State New Key Product” by the MOST, Ministry of Environmental Protection, Ministry of Commerce and General Administration of Quality Supervision, Inspection and Quarantine jointly. In 2011, the Uniflex® has received the “First Award of Science and Technology Progress in Sichuan Province” and the “Special Award of Science and Technology Progress in Chengdu”. In 2014, the Uniflex® has received the “National Award of Science and Technology Progress”. The Uniflex® has a great promotional value supported by its advantages in medication safety, energy conservation and environmental protection. Moreover, it can be dropped from a high altitude, and therefore was proved irreplaceable in the rescue and relief work of the ‘5.12’ Wenchuan Earthquake and saved numerous lives.
In June 2013, the Chinese Pharmaceutical Industry Listed Company Intellectual Property Report was released by the China Intellectual Property Research Group, which consists of MOFCOM, State Intellectual Property Office as well as the China Securities Regulatory Commission. This report shows that: Kelun Pharmaceutical ranked first in the number of both patent application and patent license in 2013 among 76 A-share listed companies (sample companies in pharmaceutical industry) with main business income, profits, R & D expenses as a percentage of the operating revenues, total patent applications, total patent licenses and total domestic trademarks as the major assessment indicators. It marks that Kelun has already stood at the leading place of technology reasearch.
Kelun upholds the tenet of "Pursue Truth in Science and Kindness in Ethics", and has set up the awareness of harmonious development with the first efficiency-oriented distribution, the second government tax-oriented distribution as well as the third social philanthropy-oriented distribution. Kelun has cumulatively donated RMB tens of millions for public welfare, Guangcai Program (poverty alleviation program) and other charity programs, presenting the company's wealth values and sense of social responsibility as well as the sound development as an outstanding private enterprise under the market economic conditions. After the “5.12” Wenchuan Earthquake, in particular, Kelun, together with its fellows, devoted itself fully to the earthquake rescue and relief. Kelun was among the first donating enterprises to its fullest capacity and the first enterprises opening the medicine land passage and dropping medicines from the air. It never suspended the production despite the intermittent aftershocks in order to keep the company running, and was one of the enterprises giving the most generous supports to the international medical rescue teams in Sichuan. Kelun performed well in this disaster. China Medical Newspaper, Medical and Economic Newspaper and other main media reported in depth on its commanding efficiency, logistics, professional capability and warrior spirit. In May 2009, because of Kelun’s excellent performance in the rescue and relief after “5.12” Wenchuan Earthquake, General Logistics Department of PLA, Mobilization Office of NDRC and State Food and Drug Administration (SFDA) presented a “Letter of Thanks” to Kelun. Mr. Liu Gexin, chairman of Kelun, was awarded “Excellent Party Member in Earthquake Rescue and Relief” by Sichuan Provincial Party Committee and Chengdu Municipal Party Committee and “Icon of Earthquake Rescue and Relief in Sichuan Province” by Sichuan Provincial Party Committee and Government. On April 20, 2013, an earthquake of magnitude 7.0 occurred in Lushan County of Ya'an, Sichuan. And Kelun, once again, acted quickly. Half an hour after the earthquake, Kelun Pharmaceutical contacted Ya'an Health Bureau, and determined the list of the first donated drugs. Two hours after the earthquake, Chairman Liu Gexin visited Ya’an affected areas, together with a team and bringing supplies.
Through the deep and sufficient integration in the capital market, Kelun Pharmaceutical will definitely create more wealth and make more magnificent achievements in the future. The company has further set the development strategy driven by "three engines". "Engine 1" - The company will go ahead in the area of IV Solutions through continuous upgrading of industrial facilities and adjustment of product development structure, consolidating and strengthening its overall advantage of products’ cluster including IV Solutions; “Engine 2” - The company will create a competitive advantage for antibiotics by implementing the complete chain from intermediates, APIs to FPPs, through innovative development and utilization of high-quality natural resources such as water, coal, and agricultural by-products, to gain a stronghold globally in the field of antibiotics; “Engine 3” - The company will make its utmost efforts for longevity through elaboration of R & D systems and diversified technology innovation, emphasizing on the R & D of high-tech drugs such as outstanding generic drugs, innovative small molecule drugs, drugs with novel delivery system, and biologicals.